Atea Pharmaceuticals Inc (NASDAQ:AVIR) price on Friday, April 11, rose 0.74% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.71.
A look at the stock’s price movement, the close in the last trading session was $2.69, moving within a range at $2.63 and $2.7365. The beta value (5-Year monthly) was 0.174. Turning to its 52-week performance, $4.14 and $2.60 were the 52-week high and 52-week low respectively. Overall, AVIR moved -11.44% over the past month.
Atea Pharmaceuticals Inc’s market cap currently stands at around $231.77 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AVIR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
AVIR’s current price about -8.68% and -10.10% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.77, while 7-day volatility ratio is 8.89% and 5.52% in the 30-day chart. Further, Atea Pharmaceuticals Inc (AVIR) has a beta value of 0.22, and an average true range (ATR) of 0.17. Analysts have given the company’s stock an average 52-week price target of $6.88, forecast between a low of $6.88 and high of $6.88. Looking at the price targets, the low is -153.87% off current price level while to achieve the yearly target high, price needs to move -153.87%. Nonetheless, investors will most likely welcome a -153.87% jump to $6.88 which is the analysts’ median price.
If we refocus on Atea Pharmaceuticals Inc (NASDAQ:AVIR), historical trading data shows that trading volumes averaged 0.3 over the past 10 days and 328.19K over the past 3 months. The company’s latest data on shares outstanding shows there are 84.46 million shares.
The 21.05% of Atea Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 63.29% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.91 million on 2025-03-14, giving us a short ratio of 10.02. The data shows that as of 2025-03-14 short interest in Atea Pharmaceuticals Inc (AVIR) stood at 476.00000000000006 of shares outstanding, with shares short falling to 2.95 million registered in 2025-02-14. Current price change has pushed the stock -19.10% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AVIR stock continues to rise going into the next quarter.
